CoChat
Sign Up
Cited by 2Lipoproteins and Cardiovascular HealthLipid metabolism and disordersCholesterol and Lipid Metabolism

Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials

Open access
Karthikeyan, Aditya, Karp, Avrohom, Maliha, Maisha, Kharawala, Amrin, Mangalesh, Sridhar, Shah, Priyansh, Modak, Vishakha, Alper, Adir +5 more·2026·American Journal of Preventive Cardiology
DOI 10.1016/j.ajpc.2026.101659PMC PMC13326082
Open this paper in CoChat — free account

Abstract

Background: Injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an established strategy to lower low-density lipoprotein cholesterol (LDL-C) and reduce atherosclerotic cardiovascular disease risk. Recently developed oral PCSK9 inhibitors may be a user-friendly alternative. Methods: A systematic search from inception through March 6, 2026, identified randomized controlled trials comparing oral PCSK9 inhibitors with placebo in adults with established atherosclerotic cardiovascular disease or at high risk of atherosclerotic cardiovascular disease, receiving background lipid-lowering therapy, or with statin intolerance. The efficacy endpoint was percentage change in lipid levels including LDL-C, apolipoprotein-B, lipoprotein(a), triglycerides, and non-HDL-C. Safety outcomes included any adverse event, serious adverse events, discontinuation due to adverse events, and new-onset or worsening of diabetes attributed to intervention. Random-effects meta-analysis was performed using restricted-maximum-likelihood estimation with Hartung-Knapp-Sidik-Jonkman adjustment. Heterogeneity was assessed using I² statistic. Results: Across five randomized phase 2 and 3 trials (n = 4226), oral PCSK9 inhibitors were associated with a significant reduction in LDL-C versus placebo (mean difference -49.92%; 95% CI -56.41 to -43.43; I² = 86%; PI, -72.30 to -27.54). Significant reductions were also observed in ApoB, Lp(a), triglycerides, and non-HDL-C. Safety outcomes were similar between both groups. In dose-matched analyses of MK-0616 at comparable dosing across trials, reductions in lipid markers remained significant with minimal heterogeneity. Conclusions: Oral PCSK9 inhibitors were associated with reductions in LDL-C, ApoB, non-HDL-C, and lipoprotein(a), with safety profile comparable to placebo. Longer-term studies evaluating cardiovascular outcomes and comparisons with injectable PCSK9 inhibitors are required to define their clinical role.

AI snapshot

Written from the paper’s full text.

TL;DR

In a systematic review and meta-analysis of five randomized phase 2/3 trials (n = 4226), oral PCSK9 inhibitors reduced LDL-C by a mean difference of −49.92% versus placebo, with significant reductions in ApoB, Lp(a), triglycerides, and non-HDL-C and safety outcomes comparable to placebo. The authors conclude the findings are hypothesis-generating, with long-term cardiovascular outcome and head-to-head injectable comparisons still needed.

Key findings

  • Across 5 RCTs (n = 4226), oral PCSK9 inhibitors significantly reduced LDL-C versus placebo: MD −49.92% (95% CI −56.41 to −43.43; I² = 86%; PI −72.30 to −27.54).
  • Significant secondary lipid reductions were also observed: ApoB MD −40.80% (95% CI −47.08 to −34.53; I² = 93.5%), Lp(a) MD −18.54% (95% CI −23.58 to −13.50; I² = 44.8%), triglycerides MD −9.77% (95% CI −18.29 to −1.25; I² = 73.1%), and non-HDL-C MD −45.68% (95% CI −52.85 to −38.5; I² = 90.8%).
  • Safety outcomes were similar to placebo: any adverse event RR 1.03 (95% CI 0.98–1.09; I² = 0%), serious adverse events RR 0.82 (95% CI 0.67–1.01; I² = 0%), discontinuation due to adverse events RR 0.75 (95% CI 0.53–1.06; I² = 0%), and new-onset/worsening diabetes RR 1.04 (95% CI 0.77–1.41; I² = 0%).
  • In dose-matched MK-0616 analyses at 20 mg, reductions remained significant with minimal heterogeneity: LDL-C MD −60.09% (95% CI −67.63 to −52.56; I² = 0%), ApoB MD −51.66% (95% CI −56.42 to −46.89; I² = 0%), non-HDL-C MD −55.82% (95% CI −60.18 to −51.46; I² = 0%), and Lp(a) MD −22.98% (95% CI −43.80 to −2.16; I² = 0%); phase 3-only LDL-C reduction was MD −60.39% (95% CI −85.73 to −35.05; I² = 0%).

Methods

  • Systematic review and meta-analysis of randomized controlled trials comparing oral PCSK9 inhibitors with placebo in adults ≥18 years with established ASCVD or high ASCVD risk, receiving background lipid-lowering therapy, or with documented statin intolerance; PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov were searched from inception through March 6, 2026, yielding 5 trials (n = 4226) with follow-up of 8–52 weeks.
  • Random-effects meta-analysis used restricted maximum likelihood for τ², Hartung–Knapp–Sidik–Jonkman adjustment for confidence intervals, and I² for heterogeneity; continuous outcomes were pooled as mean differences and dichotomous outcomes as risk ratios using Mantel–Haenszel.
  • Prespecified subgroup analyses examined dose and LDL-C determination method; sensitivity analyses excluded phase 2 trials and discontinued agents.

Limitations

  • Stated by the paper: evidence is limited to five trials with 8–52 week follow-up; trials were not powered for cardiovascular outcomes; heterogeneity from differences in populations, background lipid-lowering therapy, and trial design limits precision and generalizability; safety data are shorter than for injectable PCSK9 inhibitors (longest oral trial 52 weeks); no head-to-head comparisons with injectables exist; NNC0385-0434 was discontinued for non-clinical reasons but was included.
  • Evident from the text: pooled estimates are predominantly driven by MK-0616, the only agent with phase 3 trials, so the findings are hypothesis-generating rather than a definitive class-wide effect; publication bias was not formally assessed because k = 5; included studies were judged to have “some concerns” on RoB 2.0, with none at high risk of bias.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.ajpc.2026.101659

Cites

30 of 31 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

33 of 42 cited sources checked · 20 supported · 0 flagged · accuracy not yet measured

  • Premisecitation

    Lp(a) is not cleared predominantly through the LDL receptor.

    “Unlike LDL, Lp(a) is not cleared predominantly through the LDL receptor[27].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [27] Shapiro, 2019, Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with Evolocumab, J Am Heart Assoc source

      The Discussion (page unavailable) suggests that some Lp(a) isoforms may use clearance routes other than the LDL receptor and says Lp(a) clearance is partly regulated by that receptor. It does not establish that the LDL receptor is not the predominant clearance route overall; the claim states that stronger conclusion as fact. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
  • Premisecitation

    Inclisiran decreased LDL by ∼50% in the ORION trials.

    “Inclisiran was noted to decrease LDL by ∼50% in the ORION trials [20]”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [20] Ray, 2020, Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol, N Engl J Med source
  • Interpretationreasoning

    The discordance between the meta-analysis and Mendelian randomization studies on diabetes risk most likely arises because genetic studies reflect lifetime exposure compared to short-term pharmacological interventions.

    “Furthermore, we found no significant association between PCSK9 inhibition and diabetes (RR 1.04; 95% CI 0.77 to 1.41; I2 = 0%), despite the weak signal reported in some Mendelian randomization studies[30,31], with the discordance most likely arising from the fact that genetic studies reflect lifetime exposure as compared to short-term pharmacological interventions.”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [30] Schmidt, 2017, PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study, Lancet Diabetes Endocrinol source

      The Discussion says Mendelian randomisation estimates reflect lifetime exposure and might not directly translate to the effects of pharmacological treatment begun later in life for a shorter duration. It does not establish that this difference is the most likely cause of the discordant PCSK9 diabetes-risk findings; it says larger, longer-term trials are needed to assess that risk. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [31] Rosoff, 2025, Multiomic mendelian randomization study investigating the impact of PCSK9 and HMGCR inhibition on type 2 diabetes across five populations, Diabetes source

      The Introduction (page unavailable) notes that trials found no adverse effect of PCSK9 inhibition on diabetes risk while early MR studies suggested an increase, though more recent MR studies did not confirm it. The Discussion (page unavailable) distinguishes genetic effects of long-term HMGCR inhibition from shorter statin therapy, but does not say that exposure duration is the most likely explanation for the PCSK9 findings. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
  • Interpretationcitation

    In the MK-0616 higher dose group (18 to 20 mg), LDL-C closely tracked with ApoB, supporting a shared mechanism of particle clearance through PCSK9 inhibition.

    “In the MK-0616 higher dose group (18 to 20 mg), LDL-C closely tracked with ApoB, supporting a shared mechanism of particle clearance through PCSK9 inhibition, consistent with its known effect on LDL receptor recycling [18].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [18] Lagace, 2014, PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells, Curr Opin Lipidol source

      The sections on PCSK9 function and dysregulated PCSK9 activity explain that PCSK9 promotes LDL receptor degradation, limiting receptor recycling and affecting hepatic LDL particle clearance. The paper does not report results for MK-0616 at 18–20 mg or show that LDL-C closely tracked with ApoB in that group; it supports the mechanistic context, not the dose-specific observation. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
  • Premisecitation

    Human tracer studies with alirocumab demonstrate increased IDL and LDL ApoB fractional catabolic rates together with reduced LDL ApoB production after PCSK9 inhibition.

    “Human tracer studies with alirocumab support this mechanism, demonstrating increased IDL and LDL ApoB fractional catabolic rates together with reduced LDL ApoB production after PCSK9 inhibition.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [19] Reyes-Soffer, 2017, Effects of PCSK9 inhibition with Alirocumab on lipoprotein metabolism in healthy humans, Circulation source
  • Classified as probably not a substantial claim. 19
  • May combine two claims. 32

  • Classified as probably not a substantial claim.

    Premisecitation

    Current guidelines recommend intensifying therapy in patients who remain above LDL-C thresholds despite maximally tolerated statin treatment, typically with ezetimibe and, when greater additional lowering is required, with PCSK9-directed therapy.

    “Current guidelines recommend intensifying therapy in patients who remain above LDL-C thresholds despite maximally tolerated statin treatment, typically with ezetimibe and, when greater additional lowering is required, with PCSK9-directed therapy [1].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [1] Lloyd-Jones, 2022, 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee, J Am Coll Cardiol source

  • Classified as probably not a substantial claim.

    Study design and conductcitation

    Risk of bias for included trials was assessed independently by two reviewers using the Cochrane Risk of Bias 2.0 Tool.

    “Risk of bias for included trials was assessed independently by two reviewers, using the Cochrane Risk of Bias 2.0 Tool (Figure S2) [9].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [9] Sterne, 2019, RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ source

  • May combine two claims.

    Premisecitation

    Addition of injectable agents like evolocumab or alirocumab to intensive statin therapy lowers LDL-C by roughly 50-60% and reduces major adverse cardiovascular events in high-risk populations.

    “PCSK9 inhibition has emerged as a potent therapeutic modality, with large outcome trials showing that the addition of injectable agents like evolocumab or alirocumab to intensive statin therapy lowers LDL-C by roughly 50–60% and reduces major adverse cardiovascular events in high-risk populations [2,3].”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [2] Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med source

      The Results and Discussion report that adding evolocumab to statin therapy lowered LDL-C by 59% and reduced cardiovascular events in patients with atherosclerotic cardiovascular disease. The Trial Population section says high-intensity statins were preferred but moderate-intensity therapy was also permitted, so the finding is not limited to intensive statin therapy. This paper's outcome trial tested evolocumab, not alirocumab. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [3] Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med source

  • May combine two claims.

    Premisecitation

    Real-world use of injectable PCSK9 therapies has been constrained by persistent payor rejection, prior authorization requirements, administrative burden, and patient out-of-pocket costs.

    “Real-world use has been constrained by persistent payor rejection, prior authorization requirements, administrative burden, and patient out-of-pocket costs.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [4] Navar, 2017, Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy, JAMA Cardiol source

  • May combine two claims.

    Study design and conductown data

    Included studies were judged to have some concerns on the Cochrane RoB 2.0, with no study classified as having a high risk of bias.

    “Risk of bias was estimated with the Cochrane RoB 2.0, and the included studies were judged to have some concerns, with no study classified as having a high risk of bias.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [9] Sterne, 2019, RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ source

  • May combine two claims.

    Findingcitation

    Three studies were phase 2 trials with different dose ranges, while two were phase 3 trials evaluating a fixed dose of the medication.

    “Three studies were phase 2 trials with different dose ranges [[10], [11], [12]], while two were phase 3 trials evaluating a fixed dose of the medication [5,6].”
    Quote in the paperNot a substantial claim1 of 3 sources checked
    • cites [5] Ballantyne, 2026, Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial, JAMA source
    • cites [6] Navar, 2026, A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide, N Engl J Med source
    • cites [[10], [11], [12]]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Injectable PCSK9 inhibitors are an established strategy to lower LDL-C and reduce atherosclerotic cardiovascular disease risk.

    “Injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an established strategy to lower low-density lipoprotein cholesterol (LDL-C) and reduce atherosclerotic cardiovascular disease risk.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [2] Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med source
    • cites [3] Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductcitation

    The systematic review and meta-analysis were conducted in accordance with the Cochrane Collaboration Handbook and the PRISMA Guidelines.

    “This systematic review and meta-analysis were conducted in accordance with the recommendations of the Cochrane Collaboration Handbook [7] and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines (Figure S1) [8].”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [7] Higgins, 2024

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [8] Haddaway, 2022, PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open synthesis, Campbell Syst Rev source

  • May combine two claims.

    Premisecitation

    Recent phase 3 randomized trials, including CORALreef, showed that MK-0616 (enlicitide decanoate) produces large placebo-adjusted reductions in LDL-C, together with concordant lowering of non-HDL cholesterol, apolipoprotein B, and lipoprotein(a), and with an adverse event profile comparable to placebo.

    “Oral PCSK9 inhibitors have emerged as a promising therapeutic strategy, supported by recent phase 3 randomized trials, including the CORALreef trials, which showed that MK-0616 (renamed as enlicitide decanoate) produces large placebo-adjusted reductions in LDL-C, together with concordant lowering of non-HDL cholesterol, apolipoprotein B, and lipoprotein(a), and with an adverse event profile compar”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [5] Ballantyne, 2026, Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial, JAMA source
    • cites [6] Navar, 2026, A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide, N Engl J Med source

  • May combine two claims.

    Premisecitation

    NNC0835-0434 was discontinued for non-clinical reasons, which does not diminish its clinical relevance, and hence we included it in our analysis.

    “Of note, NNC0835–0434 was discontinued for non-clinical reasons, which does not diminish its clinical relevance, and hence we included it in our analysis [10]”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [10] Koren, 2024, PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial, Lancet Diabetes Endocrinol source

  • May combine two claims.

    Premisecitation

    PCSK9 binds hepatic LDL receptors and targets them for lysosomal degradation, thereby limiting receptor recycling and reducing hepatocyte surface receptor availability.

    “Mechanistically, PCSK9 binds hepatic LDL receptors and targets them for lysosomal degradation, thereby limiting receptor recycling and reducing hepatocyte surface receptor availability.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [18] Lagace, 2014, PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells, Curr Opin Lipidol source

  • May combine two claims.

    Premisecitation

    Lp(a) levels are driven largely by hepatic apo(a) synthesis and isoform biology, so PCSK9 inhibition only partially enhances Lp(a) removal.

    “Its levels are driven largely by hepatic apo(a) synthesis and isoform biology, so PCSK9 inhibition, despite markedly increasing LDL receptor recycling, only partially enhances Lp(a) removal [28].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [28] Moriarty, 2017, Lipoprotein(a) mass levels increase significantly according to APOE genotype, Arterioscler Thromb Vasc Biol source

      The Introduction (page unavailable) says Lp(a) levels are primarily determined by LPA variation, including kringle IV2 repeats, and describes hepatocyte apo(a) production. The Discussion (page unavailable) considers LDL-receptor clearance and PCSK9 but reports conflicting mechanisms and says the receptor’s contribution cannot be quantified. It does not establish that PCSK9 inhibition only partially enhances Lp(a) removal despite markedly increasing LDL-receptor recycling. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    PCSK9 targeted therapy preserves LDL receptor recycling, increases hepatic receptor abundance, and enhances clearance of circulating ApoB-containing lipoproteins.

    “By inhibiting this interaction, PCSK9 targeted therapy preserves LDL receptor recycling, increases hepatic receptor abundance, and enhances clearance of circulating ApoB-containing lipoproteins [18].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [18] Lagace, 2014, PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells, Curr Opin Lipidol source

  • May combine two claims.

    Premisecitation

    The net effect is a muted class response, with Lp(a) typically lowering around 20 to 30%, well below the reductions seen with LDL-C and ApoB.

    “The net effect is a muted class response, with Lp(a) typically lowering around 20 to 30%, well below the reductions seen with LDL C and ApoB [25].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [25] O’Donoghue, 2019, Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk, Circulation source

      The introduction reports that PCSK9 inhibitors reduced Lp(a) by approximately 25–30% in phase 2 trials, and the Effect of Evolocumab on Lp(a) Concentration section reports a median 26.9% reduction at 48 weeks. The paper discusses LDL-C changes but does not establish the claimed percentage-reduction comparison with both LDL-C and ApoB. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The apo(a) moiety likely shifts clearance toward non-LDLR pathways that are less responsive to PCSK9 inhibition, while any reduction in secretion appears modest.

    “The apo(a) moiety likely also shifts clearance toward non-LDLR pathways that are less responsive to PCSK9 inhibition [27], while any reduction in secretion appears modest.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [27] Shapiro, 2019, Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with Evolocumab, J Am Heart Assoc source

  • May combine two claims.

    Premisecitation

    Evolocumab in FOURIER reduced Lp(a) by a median of 26.9% at 48 weeks, and alirocumab in ODYSSEY OUTCOMES showed a median relative reduction of −23% by 4 months.

    “evolocumab in the FOURIER trial reduced Lp(a) by a median of 26.9% at 48 weeks[2,25], and alirocumab in ODYSSEY OUTCOMES showed a median relative reduction of −23% by 4 months[3,26].”
    Quote in the paperNot a substantial claim4 of 4 sources checked
    • cites [2] Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med source

      The Characteristics section reports baseline lipoprotein(a) levels, while Lipid Data reports 48-week reductions in LDL cholesterol and other lipid measures. Our copy does not report a 48-week lipoprotein(a) reduction of 26.9% (searched: lipoprotein(a), Lp(a), and 26.9%). The alirocumab clause has separate citations and is not attributed to this source. (LLM, conf=0.76)

      Experimental — accuracy not yet measured
    • cites [25] O’Donoghue, 2019, Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk, Circulation source
    • cites [3] Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med source

      The Methods identify this as the ODYSSEY OUTCOMES trial of alirocumab, but the ‘Effect of Trial Regimen on Lipid Levels’ section reports LDL cholesterol—not Lp(a)—at four months. Searches for Lp(a), lipoprotein(a), and a 23% reduction found no passage in our copy reporting the claimed median Lp(a) change. The separate FOURIER figure is attached to other citations in the citing sentence. (LLM, conf=0.76)

      Experimental — accuracy not yet measured
    • cites [26] Bittner, 2020, Effect of Alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome, JACC source

      For the alirocumab clause, the Abstract reports that ODYSSEY OUTCOMES measured lipoprotein(a) at month 4 and that alirocumab reduced it by a median of 5.0 mg/dl. The Figure 2 discussion (page not available in our copy) says levels were significantly lower at month 4, but our copy does not report the claimed median relative reduction of −23%. The evolocumab clause has separate citations and is not attributed to this source here. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    ApoB more directly reflects the number of circulating atherogenic particles than LDL-C alone, particularly when cholesterol content per particle varies, and provides a biologically relevant marker of treatment effect for therapies targeting the PCSK9 LDL receptor pathway.

    “ApoB more directly reflects the number of circulating atherogenic particles than LDL-C alone, particularly when cholesterol content per particle varies, and thus provides a biologically relevant marker of treatment effect for therapies targeting the PCSK9 LDL receptor pathway [15,16].”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [15] Soffer, 2024, Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association, J Clin Lipidol source
    • cites [16] Apolipoprotein

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Interpretationcitation

    Safety data for oral PCSK9 inhibitors remained limited, with the longest oral PCSK9 inhibitor trial duration being 52 weeks.

    “However, unlike injectable PCSK9 inhibitors, which are supported by a broad safety literature with follow-up durations extending beyond 5 years[29], safety data for oral agents remained limited, with the longest oral PCSK9 inhibitor trial duration being 52 weeks[5].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [5] Ballantyne, 2026, Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial, JAMA source

      The Trial Design reports 52 weeks of treatment, and the Assessments section says safety was monitored throughout the trial. The paper does not establish that 52 weeks was the longest duration of any oral PCSK9 inhibitor trial or explicitly assess the extent of safety data for oral agents as a class. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Evolocumab reduced LDL-C by ∼59% and alirocumab by ∼60% in the FOURIER and ODYSSEY OUTCOMES trials, respectively.

    “In comparison, evolocumab reduced LDL-C by ∼59% and alirocumab by ∼60% in the FOURIER and ODYSSEY OUTCOMES trials, respectively [2,3]”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [2] Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med source
    • cites [3] Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med source

  • May combine two claims.

    Premisecitation

    Ezetimibe lowers LDL-C by 18-25%, bempedoic acid by 17-21%, and their combination by ∼36-40%.

    “This substantially exceeded other oral non-statin therapies, as ezetimibe lowers LDL-C by 18–25%, bempedoic acid by 17–21%, and their combination by ∼36–40% [[21], [22], [23], [24]]”
    Quote in the paperSubstantial claim2 of 3 sources checked
    • cites [21] Ray, 2019, Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options, Lancet source
    • cites [22] Preiss, 2020, Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC Focus seminar, J Am Coll Cardiol source

      The Ezetimibe section reports LDL-C reductions of 19% with ezetimibe alone and 23% when added to a statin, within the claimed range. The bempedoic acid passage reports 18% when added to statins, also within the claimed range, but 22% as monotherapy. No passage in our copy supports the claimed ∼36–40% reduction for their combination (searched for the combination and its percentages). Page numbers were not available in the indexed passages. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [23] Nissen, 2023, Bempedoic acid and cardiovascular outcomes in statin-intolerant patients, N Engl J Med source

      The paper’s introductory passage reports LDL-C reductions of 17–28% with bempedoic acid, and ‘Effect on LDL Cholesterol and High-Sensitivity CRP’ reports a 21.1-percentage-point difference versus placebo at six months. Those findings support the bempedoic-acid portion broadly, but the copy does not give the claimed 18–25% reduction for ezetimibe or ∼36–40% for the combination. Page numbers were not provided for these passages. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Findingown data

    Restricting the analysis to phase 3 trials yielded significant LDL-C reduction with minimal heterogeneity (MD −60.39; 95% CI −85.73 to −35.05; I2 = 0%).

    “Restricting the analysis to only phase 3 trials, which were only available for MK-0616, yielded significant LDL-C reduction with minimal heterogeneity (MD, −60.39; 95% CI, −85.73 to −35.05; τ² = 0; I2 = 0%)”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Across trials, follow-up ranged from 8 to 52 weeks.

    “Across trials, follow-up ranged from 8 to 52 weeks.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Study design and conductnone given

    Random-effects meta-analysis was performed using the restricted maximum likelihood estimator to estimate between-study variance.

    “Random-effects meta-analysis was performed using the restricted maximum likelihood (REML) estimator to estimate between-study variance (τ²).”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Study design and conductreasoning

    Confidence intervals were calculated using the Hartung-Knapp-Sidik-Jonkman adjustment.

    “Given the limited number of studies, the confidence intervals were calculated using the Hartung–Knapp–Sidik–Jonkman (HKSJ) adjustment for a more reliable estimation.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductreasoning

    Two sensitivity analyses were performed: one excluding phase 2 trials and another excluding discontinued agents.

    “To assess robustness and address heterogeneity related to early-phase data and agent discontinuation, we performed two sensitivity analyses: one excluding phase 2 trials and another excluding discontinued agents.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    The protocol for this study was registered with PROSPERO (CRD420261345067).

    “The protocol for this study was registered with PROSPERO (CRD420261345067).”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    Two reviewers independently extracted trial-level data using a standardized template.

    “Two reviewers independently extracted trial-level data using a standardized template.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    The overall methodological quality of the included studies was considered moderate to high, supporting the robustness of the pooled analysis.

    “Based on these findings, the overall methodological quality of the included studies was considered moderate to high, supporting the robustness of the pooled analysis.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductreasoning

    Formal assessment of publication bias was not performed as funnel plot asymmetry tests and regression-based approaches are underpowered and unreliable in sparse meta-analyses (k = 5).

    “Formal assessment of publication bias was not performed as funnel plot asymmetry tests and regression-based approaches are underpowered and unreliable in sparse meta-analyses (k = 5).”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductreasoning

    Prespecified subgroup analyses were conducted based on the dose of the intervention and the method used for LDL cholesterol determination.

    “To address conceptual heterogeneity related to variation in dosing regimens and outcome assessment across trials, prespecified subgroup analyses were conducted based on the dose of the intervention and the method used for LDL cholesterol determination.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationnone given

    This is the first meta-analysis to incorporate phase 3 CORALreef trials and to perform dose-aligned analyses across oral PCSK9 inhibitors.

    “To our knowledge, this is the first meta-analysis to incorporate phase 3 CORALreef trials and to perform dose-aligned analyses across oral PCSK9 inhibitors.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Study design and conductnone given

    PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov were systematically searched from inception through March 6, 2026.

    “PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov were systematically searched from inception through March 6, 2026, to identify randomized controlled trials (RCTs) comparing oral PCSK9 inhibitors with placebo”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductreasoning

    Leave-one-out sensitivity analyses were not performed due to limited stability and interpretability in sparse meta-analyses.

    “Given the small number of included studies, leave-one-out sensitivity analyses were not performed due to limited stability and interpretability in sparse meta-analyses.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductnone given

    Two reviewers independently assessed eligibility based on full-text review, and disagreements were resolved by consensus.

    “Two reviewers independently assessed eligibility based on full-text review, and disagreements were resolved by consensus.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductcitation

    For trials evaluating multiple intervention doses, each dose arm was included as a separate comparison, with the placebo group evenly divided across intervention arms in accordance with Cochrane methodological recommendations.

    “For trials evaluating multiple intervention doses, each dose arm was included as a separate comparison, with the placebo group evenly divided across intervention arms in accordance with Cochrane methodological recommendations.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationown data

    Lp(a) levels showed more modest reductions with oral PCSK9 inhibitors (MD −18.54%; 95% CI −23.58% to −13.50%), indicating a response consistently smaller than for LDL-C and ApoB.

    “In our study, Lp(a) levels showed more modest reductions, with a pooled mean difference of −18.54% (95% CI −23.58% to −13.50%), indicating that while oral PCSK9 inhibitors do lower Lp(a), the response is consistently smaller than for LDL-C and ApoB.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S2 (checkable).

    Interpretationown data

    These findings should be interpreted as hypothesis-generating rather than establishing a class-wide effect.

    “These findings should be interpreted as hypothesis-generating rather than establishing a class-wide effect.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Ezetimibe and bempedoic acid have minimal or no effect on Lp(a), making PCSK9 inhibitors the most efficacious commercially available option for Lp(a) lowering.

    “Nonetheless, other agents such as ezetimibe and bempedoic acid have minimal or no effect on Lp(a), making PCSK9 inhibitors the most efficacious commercially available option for Lp(a) lowering [24]”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [24] Catapano, 2026, Oral PCSK9 inhibitor enlicitide versus Oral nonstatin therapies, JACC source

  • Classified as probably not a substantial claim.

    Interpretationreasoning

    Differences in study populations, background lipid-lowering therapy, and trial design may have contributed to the observed heterogeneity across lipid outcomes, further limiting the precision and generalizability of pooled estimates.

    “Finally, differences in study populations, background lipid-lowering therapy, and trial design may have contributed to the observed heterogeneity across lipid outcomes, further limiting the precision and generalizability of pooled estimates.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationown data

    Oral PCSK9 inhibitors demonstrate consistent lipid-lowering effects across early and late phase trials, with the most robust evidence derived from MK-0616.

    “Oral PCSK9 inhibitors demonstrate consistent lipid-lowering effects across early and late phase trials, with the most robust evidence derived from MK-0616.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationown data

    LDL-C calculation method alone does not account for the heterogeneity between studies; differences in exposure and trial context are likely key factors.

    “Overall, these results suggest that the LDL-C calculation method alone doesn’t account for the heterogeneity between studies, and that differences in exposure and trial context are likely the key factors.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S2 (checkable).

    Interpretationown data

    These findings should be interpreted as hypothesis-generating rather than a definitive class-wide effect across all oral PCSK9 inhibitors.

    “Hence, these findings should be interpreted as hypothesis-generating rather than a definitive class-wide effect across all oral PCSK9 inhibitors.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    Whether lipid biomarker effects translate into cardiovascular benefit remains to be established, as the current trials were not powered to evaluate cardiovascular outcomes.

    “Moreover, while our analysis focused on lipid biomarkers, whether these effects translate into cardiovascular benefit remains to be established, as the current trials were not powered to evaluate cardiovascular outcomes.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationown data

    The current evidence base is limited to five randomized trials with follow-up durations ranging from 8 to 52 weeks, which restricts statistical power and long-term inference regarding durability of outcomes.

    “The current evidence base remains limited to five randomized trials with follow-up durations ranging from 8 to 52 weeks, which restricts statistical power and long-term inference regarding the durability of outcomes.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    The pooled estimates are predominantly driven by MK-0616, the only agent with phase 3 trials available.

    “Moreover, the pooled estimates are predominantly driven by MK-0616, the only agent with phase 3 trials available.”
    Quote in the paperSubstantial claim
45 of 45

  • The paper relies on this without support.

    Atherosclerotic cardiovascular disease risk is driven by cumulative exposure to ApoB-containing lipoproteins.

    “Atherosclerotic cardiovascular disease is widely recognized to be driven by cumulative exposure to ApoB-containing lipoproteins, making intensive LDL-C reduction a cornerstone of ASCVD prevention.”
    “Because ASCVD risk is driven by cumulative exposure to ApoB-containing lipoproteins, we first examined ApoB percent change from baseline.”

  • The paper relies on this without support.

    Oral administration of PCSK9 inhibitors offers advantages over injectable therapy, such as improved access, adherence, or patient preference.

    “Recently developed oral PCSK9 inhibitors may be a user-friendly alternative.”
    “These barriers have heightened interest in orally bioavailable PCSK9 inhibitors, which may broaden access to PCSK9 pathway-based lipid-lowering through a simpler route of administration [4].”
    “Furthermore, oral agents achieve similar LDL-C reductions to their injectable counterparts and may potentially offer improved adherence and patient preference due to their once-daily dosing and oral administration. However, this advantage remains theoretical and needs head-to-head comparisons in future trials.”

  • The paper relies on this without support.

    Lp(a) is an independent and causal risk factor for atherosclerotic cardiovascular disease.

    “Lp(a), now regarded as an independent and causal risk factor for atherosclerotic cardiovascular disease, is also associated with aortic valve stenosis and can add cardiovascular risk even when LDL-C is otherwise well controlled.”
3 of 3

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Discontinued agent has a different identifier from the included agent

    Minor

    The limitations identify the discontinued agent included in the analysis as NNC0835-0434, whereas the results identify the included agent as NNC0385-0434.

  • Dose-matched analysis described as both identical-dose and 18-20 mg

    Minor

    The results say the MK-0616 dose-matched analysis used an identical 20 mg dose across studies, but the discussion describes the ApoB analysis in that subset as using doses from 18 to 20 mg.

2 of 2

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Karthikeyan, A., Karp, A., Maliha, M., Kharawala, A., Mangalesh, S., Shah, P., Modak, V., Alper, A., Doshi, A., Murli, H., Satish, V., Chi, K.-Y., & Faillace, R. T.
Affiliations
  • Albert Einstein College of Medicine (US)
  • University of Nebraska Medical Center (US)
Corresponding author
Karthikeyan, Aditya
ORCID
Venue
American Journal of Preventive Cardiology
Publisher
Elsevier BV
Published
2026-08
Volume
28
Pages
101659
ISSN
2666-6677 (ISSN-L)
DOI
10.1016/j.ajpc.2026.101659
PMC
PMC13326082
OpenAlex
W7160285690
Semantic Scholar
bc5b39289573c00c7650d337338c43dfcfe47136
Cited by
2
References
29
Citations by year
2026: 2
FWCI
5.50
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Preventive Cardiology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
PCSK9, LDL cholesterol lowering, atherosclerotic cardiovascular disease, apolipoprotein B, lipoprotein(a), triglycerides, non-HDL cholesterol, statin intolerance, lipid-lowering therapy, drug safety, diabetes risk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-19.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-19.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review